# Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

> **NCT05428150** · PHASE1 · COMPLETED · sponsor: **Excalibur Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Esbriet 267 MG Oral Capsule
- **DRUG:** EXCL-100, 600 MG Oral Tablet

## Key facts

- **NCT ID:** NCT05428150
- **Lead sponsor:** Excalibur Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-08
- **Primary completion:** 2022-09-25
- **Final completion:** 2022-09-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428150, "Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05428150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*